THBD and mesothelioma: Beyond high viability, we have also confirmed maintenance of the key mesothelioma biomarkers CK5/6, calretinin, and thrombomodulin in patient-derived organoids (c.f. Fig. 2), showing that our approach supports a degree of accurate tumor phenotype.